| Literature DB >> 17646026 |
Pierre-Yves Bochud1, Murielle Bochud, Amalio Telenti, Thierry Calandra.
Abstract
The discovery of innate immune genes, such as those encoding Toll-like receptors (TLRs), nucleotide-binding oligomerisation domain-like receptors (NLRs), and related signal-transducing molecules, has led to a substantial improvement of our understanding of innate immunity. Recent immunogenetic studies have associated polymorphisms of the genes encoding TLRs, NLRs, and key signal-transducing molecules, such as interleukin-1 receptor-associated kinase 4 (IRAK4), with increased susceptibility to, or outcome of, infectious diseases. With the availability of high-throughput genotyping techniques, it is becoming increasingly evident that analyses of genetic polymorphisms of innate immune genes will further improve our knowledge of the host antimicrobial defence response and help in identifying individuals who are at increased risk of life-threatening infections. This is likely to open new perspectives for the development of diagnostic, predictive, and preventive management strategies to combat infectious diseases.Entities:
Mesh:
Year: 2007 PMID: 17646026 PMCID: PMC7185843 DOI: 10.1016/S1473-3099(07)70185-8
Source DB: PubMed Journal: Lancet Infect Dis ISSN: 1473-3099 Impact factor: 25.071
Figure 1Overview of some available genotyping techniques
The technologies are based on four main principles. The experiments can be run on different support media and different read-out methods can be used to reveal single nucleotide polymorphisms (SNPs). Equipment costs range from a few thousand US$ ($) to over a million US$ ($$$$). Costs per SNP and per sample range from a few cents (¢) to a few dollars (¢¢¢), and tend to be lower for pricey equipments. Cost ranges indicated are purely indicative and may vary. Adapted by permission from Macmillan Publishers Ltd, reference 8, copyright (2001).
Characteristics of association and linkage studies
| Description | Associates a given allele (or set of alleles) with a disease in a population or in families | Determines the approximate chromosomal location of a gene by looking at its cosegregation with markers of known location within families |
| Participants | Population or families | Families only |
| Appropriateness for infectious diseases | Usually the most appropriate design | Families most informative for linkage (ie, with multiple affected individuals) may be very difficult and costly to collect |
| Markers | SNPs, microsatellites | Microsatellites, SNPs |
| Power to detect a small effect | High | Low |
| Population stratification bias | ||
| Relevance | Potentially important (debated) | Not an issue |
| Controlling | Can be controlled for by genotyping a set of unlinked loci or by transmission disequilibrium tests in family-based studies | Not an issue |
SNPs=single nucleotide polymorphisms.
Figure 2Recognition of microbial pathogens by the innate immune system
Microbial-associated molecular patterns are recognised by transmembrane receptors (1: eg, Toll-like receptors [TLRs]), which trigger the activation of several signal-transducing pathways, leading to the production of cytokines and expression of costimulatory molecules. Cytokines induce and regulate the inflammatory response and orchestrate the adaptive immune response. By contrast with other TLRs, TLR3, TLR7, TLR8, and TLR9 are expressed mainly in the endosomal compartment (2), where local acidification is required for recognition of microbial products by their cognate receptors. Intracellular pathogens or microbial products released intracellularly after lysis of ingested microorganisms may also interact with intracytoplasmic receptors, such as nucleotide-binding oligomerisation domain-like (NLR) proteins (3), or the RNA helicase-containing molecules (4: RIG-I or MDA5). TCR=T-cell receptor.
Figure 3Toll-like receptors (TLRs), cognate ligands, and the main signalling pathways
TLR4 detects lipopolysaccharide (LPS), mannan (Candida albicans), and the fusion protein of the respiratory syncytial virus. TLR2 forms a heterodimer with either TLR1 to detect triacyl lipopeptide or TLR6 to detect diacyl lipopeptide and zymosan. TLR2 is also involved in the recognition of lipoteichoic acid (LTA), peptidoglycan (PG), lipoarabinomannan (LAM), porins (Neisseria spp), glycosylphosphatidylinositol mucin (Trypanosoma spp; tGPI), and the haemaglutinnin protein (HA, measles virus). TLR3, TLR7, TLR8, and TLR9 are located in the endosomal compartment and detect nucleic acids and/or haemozoin (Plasmodium spp, TLR9). Through their intracellular domain, TLRs interact with specific adaptor proteins, including the myeloid differentiation primary response protein 88 (MyD88), the TIR domain-containing adaptor protein (TIRAP), the TIR domain-containing adapter inducing interferon (TRIF), and the TRIF-related adapter molecule (TRAM). These adaptors lead to the activation of several transcription factors such the nuclear factor κB (NFκB), the activating-protein 1 (AP1), and/or the interferon regulatory factors 3 and 7 (IRF3/7) that ultimately induce the production of pro-inflammatory mediators. ss=single-stranded. ds=double-stranded.
Figure 4Example of genetic variants that impair the host innate immune response
IκBα=inhibitor of nuclear factor κB (NFκB) α. IKK=inhibitor of NFκB kinase. IRAK4=interleukin-1 receptor-associated kinase 4. MyD88=myeloid differentiation primary response protein 88. TAB=TAB1, TAB2 and TAB3: TAK1-binding proteins 1–3, also known as M3K7-interacting proteins 1–3. TAK=transforming growth factor (TGF)-β-activated kinase 1, also known as mitogen-activated protein (MAP) 3 kinase 7 (M3K7). TIR=Toll-interleukin 1 receptor domain. TLR=Toll-like receptor. TRAF6=tumour necrosis factor-receptor-associated factor 6. SNP=single nucleotide polymorphism.
Association between innate immune gene polymorphisms and susceptibility to infectious diseases: complex inheritance
| Sutherland et al | -159C/T (untranslated) | Gram-negative sepsis | Increased |
| Laine et al | -159C/T (untranslated) | Periodontitis | Increased |
| Lammers et al | -159C/T (untranslated) | Pouchitis | Increased |
| Rupp et al | -159C/T (untranslated) | Increased | |
| Ouburg et al | -159C/T (untranslated) | No evidence for association | |
| Tal et al | -159C/T (untranslated) | RSV | No evidence for association |
| Szebeni et al | -159C/T (untranslated) | Necrotising enterocolitis | No evidence for association |
| Hubacek et al | 292T/G (C98G); 1306C/T (P436L) | Sepsis | Increased |
| Sutherland et al | X0/0 and 0/0 haplotype pairs | Sepsis | Increased |
| Kesh et al | 239G/C (R80T); 743A/G (N249S) | Aspergillosis | Increased |
| Sutherland et al | -16933T/A (untranslated) | Sepsis | Increased |
| Bochud et al | -15607A/G (untranslated) and haplotypes 2 and 4 | Severity of HSV2 infection | Increased |
| Yim et al | Microsatellite in intron 2 | Tuberculosis | Increased |
| Ogus et al | 2258G/A (R753Q) | Tuberculosis | Increased |
| Lorenz et al | 2258G/A (R753Q) | Sepsis | Increased |
| Moore et al | 2258G/A (R753Q) | Sepsis | No evidence for association |
| Rupp et al | 2258G/A (R753Q) | No evidence for association | |
| Schroder et al | 2258G/A (R753Q) | Lyme disease | Decreased |
| Rezazadeh et al | 896A/G(D299G) and 1196C/T(T399I) | Brucellosis | Increased |
| Tal et al | 896A/G(D299G) and 1196C/T(T399I) | RSV | Increased |
| Mockenhaupt et al | 896A/G(D299G) and 1196C/T(T399I) | Severe malaria | Increased |
| Mockenhaupt et al | 896A/G(D299G) and 1196C/T(T399I) | Manifestations of malaria | Increased |
| Montes et al | 896A/G(D299G) and 1196C/T(T399I) | Osteomyelitis | Increased |
| Balistreri et al | 896A/G(D299G) and 1196C/T(T399I) | Rickettsiosis | Increased |
| Agnese et al | 896A/G(D299G) and 1196C/T(T399I) | Sepsis | Increased |
| Lorenz et al | |||
| Barber et al | |||
| Feterowski et al | 896A/G(D299G) and 1196C/T(T399I) | Sepsis | No evidence for association |
| Child et al | |||
| Brett et al | 896A/G(D299G) and 1196C/T(T399I) | Periodontitis | Increased |
| Kinane et al | |||
| Laine et al | 896A/G(D299G) and 1196C/T(T399I) | Periodontitis | No evidence for association |
| D'Aiuto et al | |||
| Folwaczny et al | |||
| Van der Graaf et al | 896A/G(D299G) and 1196C/T(T399I) | Candidiasis | Increased |
| Van der Graaf et al | 896A/G(D299G) and 1196C/T(T399I) | Candidiasis | No evidence for association |
| Morre et al | |||
| Genc et al | 896A/G(D299G) and 1196C/T(T399I) | Bacterial vaginosis | Increased |
| Goepfert et al | 896A/G(D299G) and 1196C/T(T399I) | Bacterial vaginosis | No evidence for association |
| Newport et al | 896A/G(D299G) and 1196C/T(T399I) | Tuberculosis | No evidence for association |
| Szebeni et al | 896A/G(D299G) and 1196C/T(T399I) | Necrotising enterocolitis | No evidence for association |
| Rivera-Chavez et al | 896A/G(D299G) and 1196C/T(T399I) | Acute appendicitis | No evidence for association |
| Morre et al | 896A/G(D299G) and 1196C/T(T399I) | No evidence for association | |
| Smirnova et al, | 896A/G(D299G) and 1196C/T(T399I) | Meningococcal sepsis | No evidence for association |
| Allen et al, | |||
| Read et al | |||
| Hawn et al | 896A/G(D299G) and 1196C/T(T399I) | Legionellosis | Decreased |
| Smirnova et al | Rare mutations | Meningococcal sepsis | Increased |
| Hawn et al | 1174C/T(392stop) | Legionellosis | Increased |
| Dunstan et al | 1174C/T(392stop) | Typhoid fever | No evidence for association |
| Kesh et al | 745C/T(S249P) | Aspergillosis | Increased |
| Bochud et al | 1635A/G (P545P) and 1174G/A (untranslated) | CD4+ cells decline in HIV-1 infection | Increased |
| Mockenhaupt et al | -1486T/C | Manifestations of malaria | Increased |
| Lammers et al | -1237T/C (untranslated) | Pouchitis | Increased |
| Mockenhaupt et al | -1237T/C (untranslated) | Manifestations of malaria | No evidence for association |
| Meier et al | 3020C/ins (1007ins) | Pouchitis | Increased |
| Szebeni et al | 3020C/ins (1007ins) | Necrotising enterocolitis | No evidence for association |
| 2104C/T (R702W) | |||
| 2722G/C (G908R) | |||
HSV2=herpes simplex virus 2. IRAK4=interleukin-1 receptor-associated kinase 4. LBP=lipopolysaccharide-binding protein. MBL=mannose-binding lectin. NOD=nucleotide-binding oligomerisation domain. RSV=respiratory syncytial virus. TLR=Toll-like receptor.
Combined carriage of the CD14 -159C/T and TLR9 -1237C are associated with pouchitis; CD4 -159C/T is also known as −260C/T.
TLR1 239G/C alone and combined carriage occurrence of invasive aspergillosis.
TLR4 896A/G (D299G) is in strong linkage disequilibrium with 1196C/T (T399I); most studies analysed both 896A/G and 1196C/T with similar results.
TLR9 1635A/G is in strong linkage disequilibrium with TLR9 1174G/A.
In pregnant women with malaria, TLR4 896A/G and TLR9 T-1486T/C increased the risk of low birthweight in term infants and TLR4 A896A/G also increased the risk of maternal anaemia.
Association between innate immune gene polymorphisms and susceptibility to infectious diseases: monogenic inheritance
| 620–1AC/del (218stop); | Pyogenic bacterial infections | Increased | |
| Medvedev et al, | 821T/del (287stop); | ||
| Picard et al | 877C/T (293stop) | ||
| 94G/T (S32I) | Bacterial infections | Increased | |
| Courtois et al | |||
| 1217A/T (D406V); | Bacterial and mycobacterial infections | Increased | |
| Zonana et al, | 1249C/T (C417R); | ||
| Jain et al, | 1259A/G (X420W); other mutations |
IκBα=inhibitor of nuclear factor κB (NFκB) kinase α. IKKγ=inhibitor of NFκB kinase γ. IRAK4=interleukin-1 receptor-associated kinase 4.
Common limitations in genetic association studies
| Confounding | ||
| Population stratification | Limited information on ethnicity | |
| Failure to account for known confounders | Cohort not established in view of genetic study; insufficient clinical data; failure to adjust for multiple confounders in the analyses | |
| Selection biases | No or insufficient attempt to ensure that cases and controls come from the same source population | |
| Information biases | Information on exposure or study endpoints is gathered differently for cases and controls | |
| Limited power | No sample size calculation; insufficient sample size to detect a small effect; difficult and costly to collect large cohorts | |
| Absence of a-priori specified hypotheses | Investigators rarely distinguish between hypothesis-testing and hypothesis-generating studies | |
| No correction for multiple testing | Multiple endpoints and genetic markers are analysed, but only significant associations are reported | |
| Biological plausibility | ||
| No functional data to support association | Biological systems not sensitive enough to illustrate functional association | |
| Simplistic measure of genetic variability | Studies often limited to a few SNPs per gene | |
| Failure to account for gene–gene and gene–environment interactions | Genetic and environmental background can be expected to influence most associations | |
| Strength of the association | Any single genetic variant usually only has a small effect | |
| Consistency of the association | Results are rarely replicated across studies | |
| Dose-response effect | Alleles do not always display an additive mode of action | |
SNP=single nucleotide polymorphisms.
Examples of potential short, middle, and long-term applications and effects of innate immunogenetic studies for basic and translational research
| Basic research | Better understanding of gene function at the molecular level by the study of genetic polymorphisms | Detection of novel disease-specific genes by genomewide scans; targeted drug discovery; gene therapy (chronic infections, inherited immune deficiencies) | |
| Vaccine development | Better understanding of individual responses to vaccines | Elaboration of vaccines with improved immunogenicity (use of innate immune adjuvants) | Genetic screening at birth, allowing customised vaccination programme |
| Preventive and predictive medicine | List of crucial polymorphisms associated with increased susceptibility to infection | Screening of individuals at high risk for infectious diseases and development of individualised prophylactic measures including antimicrobial prophylaxis; identification of new therapeutic targets | Genetic screening at birth, allowing customised prophylaxis in case of high-risk condition (immunosuppressive therapy, major surgery); development of new treatment modalities |